Stock info Harvard Bioscience | Filter  Basic-Info

Harvard Bioscience

The past year was a profitable year for the Harvard Bioscience investors

Over the last 12 months, that were loss-making period for the investors in Harvard Bioscience, the stock lost around 25 percent. Over the past 5 years Harvard Bioscience' stock lost at around 18 percent in value. Harvard Bioscience's revenues between 2011 and 2015 were relatively steady and moved between 111,17 million dollars and 108,66 million dollars. Harvard Bioscience's net incomes between 2011 and 2015 were very volatile through the time and moved between 3,81 million dollars and -19,04 million dollars.

The company mostly operates in the support services sector. The global support companies gained around 20 percent worldwide over the last 10 years. Measured since 2011 the sector is 17 percent higher and over the past 12 months (December 2015-2016) there is a minus of 20 percent.

The American company didn't pay out any dividends (in the past 5 years).

Harvard Bioscience financed with relatively low debt

At the end of 2015 the support company's balance sheet was worth 120,22 million dollars. At the end of 2015 the total debt positon equaled 42,62 million dollars. This is around 35,45 percent of the total balance sheet. Last year the support company's price/earnings-ratio (PE) was around -10. So the investors valued the stock at -10 times 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the American company's market capitalization equaled around 102,79 million dollars. At the end of 2015 the American company had around 33,59 million stocks listed on the exchanges.

All the company's financial reports are available here. More information about Harvard Bioscience can be found it's website. .